Elevated White Blood Cell Levels and Thrombotic Events in Patients With Polycythemia Vera: A Real-World Analysis of Veterans Health Administration Data.
Clicks: 377
ID: 72823
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
80.9
/100
377 views
251 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #3 of 5 articles by views in clinical lymphoma, myeloma & leukemia
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Patients with polycythemia vera (PV) have a substantial risk of thrombotic events (TEs). The objective of the present analysis was to describe the association between white blood cell (WBC) levels and occurrence of TEs among patients with PV from a large real-world population.The present retrospective analysis using Veterans Health Administration claims data (October 1, 2005, to September 30, 2012) evaluated adult patients assigned to 4 WBC count categories (WBC count < 7.0, 7.0-8.4, 8.5 to < 11.0, and ≥ 11.0 × 10/L) to compare the risk of TEs (reference, WBC count, < 7.0 × 10/L group). Analysis was performed using a Cox proportional hazards model, considering WBC status as a time-dependent covariate.Of the 1565 patients with PV included in the present analysis, the WBC count was < 7.0 × 10/L for 428 (27.3%), 7.0 to 8.4 × 10/L for 375 (24.0%), 8.5 to < 11.0 × 10/L for 284 (18.1%), and ≥ 11.0 × 10/L for 478 (30.5%). Of the 1565 patients, 390 (24.9%) had experienced a TE during the study period. The mean follow-up ranged from 3.6 to 4.5 years. Compared with the reference group (WBC count < 7.0 ×10/L), the hazard ratio for TEs was 1.10 (95% confidence interval [CI], 0.82-1.48; P = .5395), 1.47 (95% CI, 1.10-1.96; P = .0097), and 1.87 (95% CI, 1.44-2.43; P < .0001) for patients with a WBC count of 7.0 to 8.4, 8.5 to < 11.0, and ≥ 11.0 ×10/L, respectively.A positive, significant association between an increased WBC count of ≥ 8.5 ×10/L and the occurrence of TEs was observed in patients with PV. The potential thrombogenic role of WBCs in patients with PV supports the continued inclusion of WBC count control in disease management and evaluation of the response to therapy.
| Reference Key |
parasuraman2019elevatedclinical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Parasuraman, Shreekant;Yu, Jingbo;Paranagama, Dilan;Shrestha, Sulena;Wang, Li;Baser, Onur;Scherber, Robyn; |
| Journal | clinical lymphoma, myeloma & leukemia |
| Year | 2019 |
| DOI |
S2152-2650(19)32120-2
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.